Cabotegravir and Lenacapavir Are Highly Effective in Preventing HIV
Cabotegravir (CAB) and lenacapavir (LEN) both offer high and similar efficacy in reducing the risk for acquiring HIV compared with no PrEP.
Cabotegravir is the...
Safety and Efficacy of Lenacapavir for Pregnant and Lactating People
For pregnant and lactating people in South Africa and Uganda, lenacapavir was efficacious, safe, and well tolerated, with no clinically significant exposure differences in...
Long-Acting Lenacapavir Is Needed to Protect Girls and Young Women Against HIV
Transitioning to long-acting pre-exposure prophylaxis (PrEP) and expanding coverage to achieve meaningful reductions in HIV incidence among adolescent girls and young women is important....
PILLAR Study: One Year Data Shows High Satisfaction With Cabotegravir
Participants in the PILLAR study were satisfied with cabotegravir long-acting injectable (CAB LA). Of those with a history of oral PrEP use, 95% reported...